Search

Your search keyword '"MESH: Antigens, Protozoan/immunology"' showing total 3 results
Start Over Descriptor "MESH: Antigens, Protozoan/immunology" Publication Year Range Last 10 years
3 results on '"MESH: Antigens, Protozoan/immunology"'

1. Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort

Author

Gregory Nuel, Paulin Sonon, Adrian J. F. Luty, Gilles Cottrell, Ibrahim Sadissou, André Garcia, Roukiyath Amoussa, Tania d’Almeida, Ambaliou Sanni, Shirley Longacre, D. Courtin, Aziz Bouraima, Florence Migot-Nabias, Rafiou Adamou, Célia Dechavanne, Michael Theisen, Kabirou Moutairou, Edmond J. Remarque, Achille Massougbodji, Jacqueline Milet, Agnès Le Port, Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique (MERIT - UMR_D 216), Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5), Laboratoire de Biochimie et de Biologie Moléculaire (Université d'Abomey Calavi, Cotonou, Bénin) (LBBM), Université d’Abomey-Calavi = University of Abomey Calavi (UAC), Universidade de São Paulo = University of São Paulo (USP), Statens Serum Institut [Copenhagen], University of Copenhagen = Københavns Universitet (UCPH), Biomedical Primate Research Centre [Rijswijk] (BPRC), Vaccinologie Parasitaire, Institut Pasteur [Paris] (IP), Laboratoire de Probabilités, Statistique et Modélisation (LPSM (UMR_8001)), Université Paris Diderot - Paris 7 (UPD7)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), This paper describes work undertaken in the context of the PALNOUGENENV, 'Paludisme-Nouvéau-né-Génétique et Environnement', a project supported by Agence Nationale pour la Recherche (projet SEST2006/040/001), Ministère des Affaires Etrangères français (projet REFS No.2006-22) for their financial support. This publication was made possible through the Faculté des Sciences de la Santé (FSS), the Institut des Sciences Biomédicales Appliquées de Cotonou (ISBA), the Programme National de Lutte contre le Paludisme (PNLP) for their institutional support and the Institut de Recherche et de Développment AIRD-ARTS and Ambassade de France à Cotonou (SCAC) for their PhD scholarships to Rafiou ADAMOU and Ibrahim SADISSOU., ANR-06-SEST-0040,PALNOURGENENV,survenue des premières infections palustres chez le noueau-né : déterminants génétiques, biologiques et environnementaux(2006), Mère et enfant face aux infections tropicales (MERIT - UMR_D 216), University of Abomey Calavi (UAC), University of São Paulo (USP), University of Copenhagen = Københavns Universitet (KU), Institut Pasteur [Paris], and Laboratoire de Probabilités, Statistiques et Modélisations (LPSM (UMR_8001))

Subjects
Male, Protozoan Proteins, Antibodies, Protozoan, MESH: Malaria, Falciparum/immunology, 0302 clinical medicine, MESH: Pregnancy, MESH: Antigens, Protozoan/immunology, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Pregnancy, Surveys and Questionnaires, Benin, 030212 general & internal medicine, MESH: Plasmodium falciparum/immunology, Longitudinal Studies, Malaria, Falciparum, MESH: Longitudinal Studies, MESH: Antibodies, Protozoan/blood, biology, Malaria vaccine, MESH: Infant, Newborn, MESH: Enzyme-Linked Immunosorbent Assay, MESH: Infant, 3. Good health, Infectious Diseases, [SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology, Cytophilic IgG, Female, Merozoite vaccine candidate antigens, Antibody, medicine.symptom, lcsh:Arctic medicine. Tropical medicine, lcsh:RC955-962, 030231 tropical medicine, Plasmodium falciparum, Context (language use), Antigens, Protozoan, Enzyme-Linked Immunosorbent Assay, Asymptomatic, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, MESH: Benin, Antigen, Immunity, parasitic diseases, medicine, Humans, lcsh:RC109-216, MESH: Surveys and Questionnaires, MESH: Humans, business.industry, Research, Infant, Newborn, Infant, biology.organism_classification, medicine.disease, MESH: Protozoan Proteins/immunology, MESH: Male, Malaria, Immunoglobulin G, Immunology, biology.protein, Parasitology, business, MESH: Immunoglobulin G/blood, MESH: Female
Abstract

BACKGROUND: Substantial evidence indicates that cytophilic IgG responses to Plasmodium falciparum merozoite antigens play a role in protection from malaria. The specific targets mediating immunity remain unclear. Evaluating antibody responses in infants naturally-exposed to malaria will allow to better understand the establishment of anti-malarial immunity and to contribute to a vaccine development by identifying the most appropriate merozoite candidate antigens.METHODS: The study was based on parasitological and clinical active follow-up of infants from birth to 18 months of age conducted in the Tori Bossito area of southern Benin. For 399 infants, plasma levels of cytophilic IgG antibodies with specificity for five asexual stage malaria vaccine candidate antigens were determined by ELISA in infants' peripheral blood at 6, 9, 12 and 15 months of age. Multivariate mixed logistic model was used to investigate the association between antibody levels and anti-malarial protection in the trimester following the IgG quantification. Moreover, the concentrations of merozoite antigen-specific IgG were compared between a group of infants apparently able to control asymptomatic malaria infection (CAIG) and a group of infants with no control of malaria infection (Control group (NCIG)). Protective effect of antibodies was also assessed after 15 months of malaria exposure with a Cox regression model adjusted on environmental risk.RESULTS: Cytophilic IgG responses to AMA1, MSP1, MSP2-3D7, MSP2-FC27, MSP3 and GLURP R2 were associated with increasing malarial infection risk in univariate analysis. The multivariate mixed model showed that IgG1 and IgG3 to AMA1 were associated with an increased risk of malarial infection. However infants from CAIG (n = 53) had significantly higher AMA1-, MSP2-FC27-, MSP3-specific IgG1 and AMA1-, MSP1-, MSP2-FC27-, MSP3 and GLURP-R2-specific IgG3 than those from NCIG (n = 183). The latter IgG responses were not associated with protection against clinical malaria in the whole cohort when protective effect is assessed after 15 months of malaria exposition.CONCLUSION: In this cohort, merozoite antigen-specific cytophilic IgG levels represent a marker of malaria exposure in infants from 6 to 18 months of age. However, infants with resolution of asymptomatic infection (CAIG) seem to have acquired naturally immunity against P. falciparum. This observation is encouraging in the context of the development of multitarget P. falciparum vaccines.

Published
2019
Full Text
View/download PDF

2. Bystander immunotherapy as a strategy to control allergen-driven airway inflammation

Author

Sébastien Fleury, Severine Navarro, Nicolas Glaichenhaus, A Kanda, David Dombrowicz, Anne Lazzari, Valérie Julia, Immunologie des muqueuses et inflammation, Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Institut de pharmacologie moléculaire et cellulaire (IPMC), Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA), Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 (RNMCD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM), This work was supported by a grant from the Fondation pour la Recherche Médicale and INSERM. S.N. was supported by a fellowship from the FRM, A.L. was supported by a fellowship from Vaincre la Mucoviscidose, and A.K is supported by a grant from the Agence Nationale de la Recherche (ANR)., We thank Nicolas Guy and the animal facility staff for their excellent animal care, as well as Julie Cazareth for the cell sorting experiments., Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), and Derudas, Marie-Hélène

Subjects
immune tolerance, T reg, medicine.medical_treatment, Protozoan Proteins, MESH: Ovalbumin/administration & dosage, MESH: Asthma/immunology, airway inflammation, Lymphocyte Activation, medicine.disease_cause, Immunoglobulin E, T-Lymphocytes, Regulatory, Mice, Th2, 0302 clinical medicine, Allergen, MESH: Antigens, Protozoan/immunology, Immunology and Allergy, CTLA-4 Antigen, MESH: Animals, IL-2 receptor, Desensitization (medicine), MESH: Immunoglobulin E/immunology, MESH: Th2 Cells/metabolism, 0303 health sciences, MESH: T-Lymphocytes, Regulatory/immunology, biology, respiratory system, MESH: Ovalbumin/immunology, MESH: Respiratory Hypersensitivity/metabolism, MESH: CTLA-4 Antigen/metabolism, 3. Good health, MESH: T-Lymphocytes, Regulatory/metabolism, [SDV.IMM]Life Sciences [q-bio]/Immunology, Bronchoalveolar Lavage Fluid, specific immunotherapy, MESH: Respiratory Hypersensitivity/immunology, MESH: Desensitization, Immunologic*/methods, [SDV.IMM] Life Sciences [q-bio]/Immunology, Ovalbumin, MESH: Mice, Transgenic, Immunology, MESH: Asthma/metabolism, Antigens, Protozoan, Mice, Transgenic, Article, Inducible T-Cell Co-Stimulator Protein, 03 medical and health sciences, Th2 Cells, MESH: Inducible T-Cell Co-Stimulator Protein/metabolism, Antigen, In vivo, MESH: Allergens/administration & dosage, Respiratory Hypersensitivity, medicine, Animals, MESH: Mice, 030304 developmental biology, business.industry, MESH: Interleukin-2 Receptor alpha Subunit/metabolism, Interleukin-2 Receptor alpha Subunit, Immunotherapy, Allergens, asthma, MESH: Protozoan Proteins/immunology, MESH: Lymphocyte Activation/immunology, MESH: Th2 Cells/immunology, respiratory tract diseases, MESH: Respiratory Hypersensitivity/therapy, Disease Models, Animal, Desensitization, Immunologic, MESH: Bronchoalveolar Lavage Fluid/immunology, biology.protein, MESH: Allergens/immunology, MESH: Disease Models, Animal, business, MESH: Asthma/therapy, 030215 immunology
Abstract

International audience; Allergic asthma is a chronic inflammatory disease characterized by airway hyperresponsiveness (AHR), lung infiltration of Th2 cells, and high levels of IgE. To date, allergen-specific immunotherapy (SIT) is the only treatment that effectively alleviates clinical symptoms and has a long-term effect after termination. Unfortunately, SIT is unsuitable for plurisensitized patients, and highly immunogenic allergens cannot be used. To overcome these hurdles, we sought to induce regulatory CD4(+) T cells (Treg) specific to an exogenous antigen that could be later activated as needed in vivo to control allergic responses. We have established an experimental approach in which mice tolerized to ovalbumin (OVA) were sensitized to the Leishmania homolog of receptors for activated c kinase (LACK) antigen, and subsequently challenged with aerosols of LACK alone or LACK and OVA together. Upon OVA administration, AHR and allergic airway responses were strongly reduced. OVA-induced suppression was mediated by CD25(+) Treg, required CTLA-4 and ICOS signaling and resulted in decreased numbers of migrating airway dendritic cells leading to a strong impairment in the proliferation of allergen-specific Th2 cells. Therefore, inducing Treg specific to a therapeutic antigen that could be further activated in vivo may represent a safe and novel curative approach for allergic asthma.Mucosal

Published
2015
Full Text
View/download PDF

3. Immunoadjuvant Properties of the Rho Activating Factor CNF1 in Prophylactic and Curative Vaccination against Leishmania infantum

Author

Laurent Boyer, Emmanuel Lemichez, Nassim Mathal, Bernard Ferrua, Daniel Gillet, Patrick Munro, Pierre Marty, Grégory Michel, Toxines bactériennes dans la relation hôtes-pathogènes, Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-IFR50-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Centre méditerranéen de médecine moléculaire (C3M), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Nice (CHU Nice), Service d'Ingénierie Moléculaire pour la Santé (ex SIMOPRO) (SIMoS), Médicaments et Technologies pour la Santé (MTS), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), This work was supported by the Groupe d’Action Contre la Leishmaniose (GACL), by institutional funding from INSERM, grants from the Fondation Infectiopôle Sud, the Agence Nationale de la Recherche (ANR 11BSV3 004 01), the 'Investments for the Future' LABEX SIGNALIFE ANR-11-LABX-0028-01 and the C3M animal facility. NM was supported by DGA and the joint ministerial program of R&D against CBRNE threats. SIMOPRO is a member of the laboratory of Excellence LERMIT supported by the grant from the Agence Nationale de la Recherche (ANR-10-LABEX-33)., We are grateful to Dr Mery Tulic and Carmelo Luci for critical reading of the manuscript. We thank Veronique Corcelle and the C3M animal facility team (Yannick Michelle, Sandrine Verger and Alexandre Ipekdjian) for their help and valuable assistance with animal care., ANR-11-LABX-0028,SIGNALIFE,Réseau d'Innovation sur les Voies de Signalisation en Sciences de la Vie(2011), ANR-11-IDEX-0003,IPS,Idex Paris-Saclay(2011), Université Nice Sophia Antipolis (1965 - 2019) (UNS), and COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA)

Subjects
0301 basic medicine, Life Cycles, MESH: Bacterial Toxins/genetics, Physiology, T-Lymphocytes, [SDV]Life Sciences [q-bio], MESH: Escherichia coli Proteins/metabolism, lcsh:Medicine, [SDV.BC.BC]Life Sciences [q-bio]/Cellular Biology/Subcellular Processes [q-bio.SC], Protozoology, Mice, 0302 clinical medicine, MESH: Antigens, Protozoan/immunology, Immune Physiology, [SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB], Medicine and Health Sciences, Public and Occupational Health, MESH: Animals, MESH: Administration, Intranasal, Leishmania infantum, Enzyme-linked immunoassays, lcsh:Science, MESH: Immunity, Humoral/immunology, Protozoans, Leishmania, Mice, Inbred BALB C, MESH: Leishmania infantum/pathogenicity, Multidisciplinary, biology, Escherichia coli Proteins, Vaccination, MESH: Interleukin-2/metabolism, Parasitic diseases, MESH: Bacterial Toxins/metabolism, 3. Good health, MESH: Immunity, Humoral/physiology, medicine.anatomical_structure, MESH: Vaccination/methods, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, 030220 oncology & carcinogenesis, Vaccination and immunization, Female, Protozoan Life Cycles, Research Article, Bacterial Toxins, Immunology, MESH: Interleukin-4/metabolism, MESH: Mice, Inbred BALB C, Antigens, Protozoan, Spleen, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Research and Analysis Methods, MESH: Leishmania infantum/immunology, Microbiology, Immunoadjuvant, 03 medical and health sciences, Immune system, Antigen, MESH: Escherichia coli Proteins/genetics, MESH: T-Lymphocytes/immunology, medicine, Animals, Immune response, Immunoassays, MESH: Mice, Administration, Intranasal, business.industry, Intracellular parasite, Promastigotes, lcsh:R, Organisms, Biology and Life Sciences, biology.organism_classification, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Parasitic Protozoans, Immunity, Humoral, 030104 developmental biology, Humoral immunity, Immunologic Techniques, Interleukin-2, lcsh:Q, Interleukin-4, Preventive Medicine, business, MESH: Female, Developmental Biology
Abstract

International audience; There is a need to develop new effective immunoadjuvants for prophylactic or therapeutic vaccines against intracellular pathogens. The activation of Rho GTPases by bacterial cytotoxic necrotizing factor 1 (CNF1) elicits humoral protective responses against protein antigens. Here, we set out to investigate whether CNF1 activity initiates humoral immunity against co-administered parasite antigens and anti-microbial immune signaling. We report that co-administration of wild-type (WT) CNF1 with Leishmania (L.) promastigote antigens at the nasal mucosa triggered prophylactic and curative vaccine responses against this parasite. Vaccination of the mucosa with promastigote lysate antigens combined with WT CNF1 conferred protection against high inoculum L. infantum infection, which reached 82% in the spleen. Immune parameter analysis by antigen recall indicated robust T-helper (Th)1 polarization of immune memory cells, with high IL-2 and IFN-γ production combined with decreased IL-4 production. Additionally, we explored the curative effect of WT CNF1 on previously infected animals. We observed that PL combined with WT CNF1, but not the inactive C866S mutant CNF1 (mCNF1), induced a 58% decrease in the parasite burden in the spleen.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results